Importantly, combination of the autophagy inhibitor HCQ with Doxo dramatically diminishes the superiority of the CAV1 KD tumors (Figures 7C–7F), suggesting a possible stratagem to overcome Doxo resistance in CAV1-downregulated breast cancer patients by targeting autophagy. The gene discussed is CAV1; the disease is breast carcinoma.